Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

184.39
-1.7500-0.94%
Post-market: 184.390.00000.00%19:30 EDT
Volume:1.03M
Turnover:191.41M
Market Cap:9.66B
PE:-48.93
High:188.00
Open:186.51
Low:184.00
Close:186.14
52wk High:260.19
52wk Low:117.30
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.17
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:115.94
PE(LYR):-50.08

Loading ...

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Simply Wall St.
·
Aug 04

Earning Preview: Axsome Therapeutics revenue is expected to increase by 59.29%, and institutional views are predominantly bullish

Earnings Agent
·
Aug 03

Axsome Therapeutics is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)

Simply Wall St.
·
Jul 27

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Simply Wall St.
·
Jul 25

Axsome, Five Below, APPS, Intuit, Adobe Trending With Analysts

TIPRANKS
·
Jul 25

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

MT Newswires Live
·
Jul 21

U.S. Research Roundup-colgate-palmolive, IBM, Unitedhealth

Reuters
·
Jul 21

Axsome Therapeutics initiated with an Outperform at BMO Capital

TIPRANKS
·
Jul 21

Axsome Therapeutics Price Target Maintained with a $290.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 16

Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application

MT Newswires Live
·
Jul 15

Axsome Says FDA Accepts Axs-12 Narcolepsy Cataplexy NDA, Sets May 1, 2027 PDUFA Date

Reuters
·
Jul 15

Axsome Therapeutics - FDA Sets Pdufa Target Action Date of May 1, 2027 for Axs-12 Nda

THOMSON REUTERS
·
Jul 15

Axsome Therapeutics - FDA Does not Plan Advisory Committee Meeting for Axs-12 Nda

THOMSON REUTERS
·
Jul 15

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for Axs-12 for the Treatment of Cataplexy in Narcolepsy

THOMSON REUTERS
·
Jul 15

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Axsome Therapeutics (AXSM) and Nurix Therapeutics (NRIX)

TIPRANKS
·
Jul 14

Axsome Therapeutics to Report Q2 Financial Results, Host Conference Call

Reuters
·
Jul 14